(Q33811929)

29 July 2017

1 reference

title

Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance (English)

1 reference

29 July 2017

1 reference

1

Siddik ZH

1 reference

29 July 2017

Hagopian GS

2

1 reference

29 July 2017

Thai G

3

1 reference

29 July 2017

Tomisaki S

4

1 reference

29 July 2017

Toyomasu T

5

1 reference

29 July 2017

Khokhar AR

6

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Journal of Inorganic Biochemistry

29 July 2017

published in

1 reference

29 July 2017

volume

77

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

65-70

1 reference

Platinum Compounds: a New Class of Potent Antitumour Agents

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Cisplatin (cis-diamminedichloroplatinum II)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Drugs five years later. Cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

High-Dose Cisplatin in Hypertonic Saline

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

High-dose cisplatin with sodium thiosulfate protection.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Phase I studies with carboplatin at the Royal Marsden Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Preclinical studies identifying carboplatin as a viable cisplatin alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Ovarian trials at the Royal Marsden.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Ovarian cancer: new clinical approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Chemotherapy for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

New platinum antitumor complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Modulation of cis-diamminedichloroplatinum(II) resistance: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

New therapies for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Interaction of the antitumor agents cis,cis,trans-PtIV(NH3)2Cl2(OH)2 and cis,cis,trans-PtIV[(CH3)2CHNH2]2Cl2(OH)2 and their reduction products with PM2 DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Glutathione-mediated activation of anticancer platinum(IV) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Resistance to platinum compounds: mechanisms and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

Cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900144-0

7 January 2021

10.1016/S0162-0134(99)00144-0

Identifiers

DOI

1 reference

29 July 2017

1 reference